10-Q: Royalty Pharma Q3 2025: Internalization Shifts Expenses, Portfolio Receipts Rise

Royalty Pharma reports a decline in GAAP net income and EPS for Q3 and the first nine months of 2025, primarily due to accounting changes from its internalization and increased R&D funding, while Portfolio Receipts show strong growth.

Summary

• Net income attributable to Royalty Pharma plc decreased by 47.0% to $288.2 million for the three months ended September 30, 2025, compared to $544.0 million in the prior year period.
• Diluted earnings per Class A ordinary share decreased to $0.67 for Q3 2025 from $1.21 for Q3 2024.
• For the nine months ended September 30, 2025, net income attributable to Royalty Pharma plc decreased by 14.4% to $556.7 million, down from $650.8 million in the same period of 2024.
• Diluted earnings per Class A ordinary share for the nine months ended September 30, 2025, was $1.28, a decrease from $1.44 in the prior year period.
• Total income and other revenues increased by 7.9% to $609.3 million for Q3 2025 and by 5.2% to $1.76 billion for the first nine months of 2025.
• Portfolio Receipts, a key cash flow metric, increased by 10.8% to $813.6 million for Q3 2025 and by 15.6% to $2.38 billion for the first nine months of 2025.
• General and administrative (G&A) expenses significantly increased by 109.3% to $118.7 million for Q3 2025 and by 142.0% to $409.2 million for the first nine months of 2025, primarily due to higher share-based compensation and employee compensation expenses following the May 2025 internalization.
• Research and development (R&D) funding expense surged to $50.5 million for Q3 2025 and $401.5 million for the first nine months of 2025, driven by new funding arrangements for daraxonrasib and litifilimab.
• The company repurchased 35.4 million Class A ordinary shares at a cost of approximately $1.2 billion in the first nine months of 2025, with approximately $1.9 billion remaining under the new $3.0 billion share repurchase program.
• New investments totaling $1.7 billion were made in royalties, milestones, and other contractual receipts during the first nine months of 2025, including significant acquisitions for Imdelltra, daraxonrasib, and litifilimab.

Sentiment

Score: 6

Explanation: While GAAP net income and EPS declined significantly due to accounting impacts from internalization and increased R&D funding, the underlying cash flow metric (Portfolio Receipts) showed strong growth. The company also made substantial new investments and continued its share repurchase program, indicating operational strength and strategic deployment of capital. The negative GAAP results are largely due to non-cash accounting adjustments rather than a fundamental deterioration of the business's cash-generating ability, leading to a moderately positive sentiment.

Positives

• Portfolio Receipts, a key cash flow metric, increased by 10.8% to $813.6 million for the three months ended September 30, 2025, and by 15.6% to $2.38 billion for the nine months ended September 30, 2025, demonstrating strong underlying cash generation.
• Significant new investments were made, totaling $1.7 billion in royalties, milestones, and other contractual receipts during the first nine months of 2025, expanding the portfolio with assets like Imdelltra, daraxonrasib, and litifilimab.
• The company authorized a new $3.0 billion share repurchase program in January 2025, repurchasing 35.4 million shares for approximately $1.2 billion in the first nine months of 2025, indicating confidence in valuation and returning capital to shareholders.
• Royalty Receipts from the cystic fibrosis franchise increased by $45.6 million (7.4%) in the first nine months of 2025, driven by strong global demand for Trikafta/Kaftrio and favorable U.S. pricing.
• Trelegy Royalty Receipts grew by $27.9 million (13.3%) in the first nine months of 2025 due to continued volume growth and increased market share.
• Xtandi Royalty Receipts increased by $21.1 million (17.2%) in the first nine months of 2025, attributable to sales growth across all regions, particularly in the United States.
• Evrysdi Royalty Receipts increased by $19.5 million (16.6%) in the first nine months of 2025, driven by incremental royalties acquired and strong global growth.
• Tremfya Royalty Receipts increased by $21.7 million (21.6%) in the first nine months of 2025, due to market share gains and strong uptake in new indications.
• Voranigo Royalty Receipts were $79.5 million in the first nine months of 2025, primarily driven by its strong launch in the United States after its FDA approval in August 2024.
• Positive clinical developments were reported for several development-stage product candidates, including accelerated data readout for litifilimab (H2 2026), positive Phase 2 results for obexelimab, initiation of Phase 3 for trontinemab, and positive Phase 1 results for daraxonrasib leading to a planned Phase 3 trial in Q4 2025 and an FDA priority review voucher.
• The internalization of management, completed on May 16, 2025, is expected to enhance alignment with shareholders, increase investment returns, and improve governance by eliminating external management fees.

Negatives

• Net income attributable to Royalty Pharma plc decreased by 47.0% to $288.2 million for Q3 2025 and by 14.4% to $556.7 million for the first nine months of 2025, compared to the prior year periods.
• Diluted earnings per Class A ordinary share decreased to $0.67 for Q3 2025 and $1.28 for the first nine months of 2025, down from $1.21 and $1.44, respectively, in the prior year periods.
• General and administrative expenses increased significantly by 109.3% for Q3 2025 and 142.0% for the first nine months of 2025, primarily due to higher employee compensation and share-based compensation expenses post-internalization, and $29.6 million in acquisition-related costs for the internalization.
• Research and development funding expense increased substantially by $50.0 million for Q3 2025 and $400.0 million for the first nine months of 2025, reflecting new funding arrangements.
• Interest expense increased by 19.6% for Q3 2025 and 33.6% for the first nine months of 2025, driven by the assumption of a $380 million term loan and the issuance of $2.0 billion in senior unsecured notes.
• Royalty Receipts from Tysabri decreased by $16.3 million (8.1%) in the first nine months of 2025 due to increased competition and decreased pricing in the rest of the world.
• Imbruvica Royalty Receipts decreased by $14.6 million (10.1%) in the first nine months of 2025, reflecting competitive pressures and the impact of Medicare Part D redesign.
• Promacta Royalty Receipts were relatively flat in the first nine months of 2025, with the U.S. launch of a generic (eltrombopag) in May 2025 posing future competitive pressure.
• The company is in a dispute with Vertex regarding the full amount of royalty receipts on Alyftrek net sales, which could impact future royalty income if not resolved favorably.
• The provision for changes in expected cash flows from financial royalty assets resulted in an expense of $12.1 million for Q3 2025, primarily due to declines in sell-side consensus sales forecasts for Evrysdi.

Risks

• Biopharmaceutical product sales may be lower than expected due to pricing pressures, insufficient demand, product competition, clinical trial failures, lack of market acceptance, changes in marketer priorities, obsolescence, lack of acceptance by healthcare programs, loss of patent protection, or government regulations.
• The royalty market may not grow at the same rate as in the past, or at all, potentially limiting the ability to acquire sufficient royalties to sustain business growth.
• Acquisitions of royalties on development-stage biopharmaceutical product candidates are subject to additional risks, including failure to receive regulatory approval, timely market entry, or commercial success, which could lead to non-cash impairment charges.
• Strategic acquisitions of operating biopharmaceutical companies or securities of biopharmaceutical companies may not realize expected benefits and could expose the company to new liabilities or divert management's attention.
• The use of leverage magnifies potential for loss if acquired royalties do not generate sufficient income, and increased interest rates could raise borrowing costs.
• The success of the business depends on key members of the team, and their departure or competing demands on their time could adversely affect operations.
• Conflicts of interest may arise between the company and its personnel, particularly with Mr. Legorreta's involvement in Pharmakon Advisors and other entities.
• The company's ability to generate sufficient cash to service indebtedness and meet liquidity needs depends on factors beyond its control, and a shortfall could force asset sales.
• The business is subject to interest rate, foreign exchange, inflation, and banking industry risks, including potential losses from bank insolvencies.
• Information available about underlying biopharmaceutical products may be limited, leading to actual cash flow being significantly lower than estimates.
• Future income is dependent upon numerous royalty-specific assumptions (product sales, competition, patent expirations, etc.) which, if inaccurate, could result in lower returns or permanent impairment.
• Most royalties are classified as financial assets measured at amortized cost using the effective interest method, making GAAP results of operations volatile and unpredictable due to non-cash charges from changes in sales forecasts.
• Reliance on a limited number of products (top five accounted for 60% of Royalty Receipts in the first nine months of 2025) exposes the company to significant deterioration if these products underperform.
• Intense competition exists in acquiring royalties, potentially leading to fewer opportunities or lower projected returns.
• Biopharmaceutical products are subject to substantial competition, obsolescence, and governmental/regulatory actions that could diminish sales and royalty payments.
• Marketers of products generating royalties are outside of the company's control, and their strategic decisions, resource allocation, or operational issues could adversely affect royalty payments.
• License agreements may be unilaterally terminated or disputes may arise, affecting royalty payments and potentially limiting the company's ability to enforce rights.
• The insolvency of a marketer could delay or impede royalty payments, potentially resulting in unsecured claims or the need for new distribution efforts.
• Unsuccessful attempts to acquire new royalties can result in significant costs, inefficient use of management time, and reputational harm.
• Healthcare reimbursement policies, managed care considerations, and pricing pressures (e.g., Inflation Reduction Act) can negatively affect product sales and royalty values.
• Federal government deficit reduction policies could reduce the value of royalties held.
• Sales of products are subject to regulatory approvals and actions in the U.S. and foreign jurisdictions, and manufacturing/distribution can be interrupted by regulatory agencies or supplier deficiencies.
• Product liability claims against developers, manufacturers, or marketers could diminish returns on biopharmaceutical products.
• The company is typically not involved in maintaining, enforcing, and defending patent rights, relying on partners, and any loss or reduction in patent protection could decrease royalty payments.
• Third-party patents may result in additional costs for marketers and reduce royalty payments.
• Disclosure of trade secrets by marketers could negatively affect the competitive position of products.
• The board of directors may decide to use cash for asset acquisitions or operations instead of paying dividends or repurchasing shares, potentially affecting share price.
• The company expects to be classified as a PFIC for U.S. federal income tax purposes, which could subject U.S. holders to adverse tax consequences and make Class A ordinary shares less attractive.
• Cybersecurity vulnerabilities, information system failures, and risks associated with artificial intelligence-based software could result in information theft, data corruption, business disruption, and legal liability.
• Changes in accounting standards may adversely affect financial statements.
• Outbreaks of infectious or contagious diseases could severely impact global economic activity, destabilize markets, affect partners, and disrupt clinical trials or supply chains.
• Legal claims and proceedings, regardless of merit, can incur significant costs and divert management's attention.
• Corporate responsibility matters and related reporting obligations may impact the business, requiring additional investments and posing reputational risks.

Future Outlook

The company anticipates continued investment in new royalties as fundamental to long-term growth, supplementing existing portfolio growth and offsetting declines from products losing market exclusivity. Management expects to continue evaluating a continuous array of royalty acquisition opportunities. The data readout for litifilimab Phase 3 studies is accelerated to the second half of 2026, and Zenas BioPharma anticipates reporting 24-week data for obexelimab in relapsing multiple sclerosis in the first quarter of 2026. Roche plans to initiate a Phase 3 study for trontinemab in preclinical Alzheimer's disease. Revolution Medicines plans to initiate a Phase 3 trial for daraxonrasib in 1L metastatic PDAC in the fourth quarter of 2025. Pharvaris anticipates topline data for deucrictibant Phase 3 study in Q4 2025, with an expected NDA submission in H1 2026. The company expects to continue funding current and planned operating costs principally through cash flow from operations and investments through cash flow and issuances of equity and debt. The company also expects to exclude the portion of total General and administrative expenses attributable to cash employee compensation for personnel of RP Manager from its assessment of internal control over financial reporting for the year ending December 31, 2025.

Management Comments

• "Our operations have historically been financed primarily with cash flows generated by our royalties."
• "We believe there is no direct correlation between income from financial royalty assets and royalty receipts due to the nature of the accounting methodology applied for financial royalty assets."
• "We believe that our existing capital resources, cash provided by operating activities and access to our Revolving Credit Facility will continue to allow us to meet our operating and working capital requirements, to fund planned strategic acquisitions and R&D funding arrangements, and to meet our debt service obligations for the foreseeable future."
• "Our low operating costs coupled with a lack of capital expenditures and low taxes have contributed to our strong financial profile, resulting in high operating leverage and high cash flow conversion."
• "We expect to continue funding our current and planned operating costs (excluding acquisitions) principally through our cash flow from operations and investments through cash flow and issuances of equity and debt."
• "While volatility exists in the funding of new acquisitions on a year-to-year basis due to the unpredictable timing of new investment opportunities, we have consistently deployed significant amounts of cash when measured over multi-year periods."
• "Our approach is rooted in a highly disciplined evaluation process that is not dictated by a minimum annual investment threshold."

Industry Context

Royalty Pharma operates as the largest buyer of biopharmaceutical royalties and a leading funder of innovation, positioning itself uniquely in the industry. The company's strategy of acquiring royalties on both commercial and development-stage products allows it to participate in the growth of the biopharmaceutical sector without direct R&D and commercialization risks. The significant R&D funding expenses and new royalty acquisitions reflect a robust pipeline of innovative therapies and a continued demand for alternative funding solutions by biopharmaceutical companies. The increase in interest expense and the issuance of new senior unsecured notes indicate a reliance on debt capital to fuel growth, a common strategy for companies with predictable cash flow streams like royalties. The ongoing public scrutiny of drug pricing and the impact of legislation like the Inflation Reduction Act highlight a challenging regulatory environment that could affect future royalty revenues, though the company's diversified portfolio helps mitigate some product-specific risks. The internalization of management is a notable trend in the asset management space, aiming to align incentives and potentially reduce costs over the long term.

Comparison to Industry Standards

• Royalty Pharma's business model, focused on acquiring biopharmaceutical royalties, is distinct from traditional pharmaceutical companies like Pfizer or Johnson & Johnson, which bear full R&D and commercialization risks. Instead, it's more comparable to specialized investment funds or private equity firms in the life sciences sector, such as BioPharma Credit PLC (managed by Pharmakon Advisors, with which Pablo Legorreta has ties), which also provides debt capital to the biopharmaceutical industry.
• The company's Portfolio Receipts growth of 15.6% for the first nine months of 2025 demonstrates strong cash generation, which is a critical metric for royalty-based businesses and compares favorably to many traditional pharma companies that might experience slower top-line growth due to patent cliffs or pipeline challenges.
• The substantial increase in R&D funding expense ($400 million for nine months 2025) reflects a high level of investment in future growth, a characteristic shared with innovative biotech companies, but Royalty Pharma's approach is through funding partnerships rather than direct R&D, diversifying risk.
• The decline in GAAP net income and EPS, while significant, is heavily influenced by non-cash accounting adjustments related to the effective interest method and the internalization. This volatility is inherent to its accounting model and makes direct GAAP net income comparisons to traditional operating companies less meaningful without considering the underlying cash flow (Portfolio Receipts).
• The $3.0 billion share repurchase program and $1.2 billion in repurchases for the first nine months of 2025 indicate a strong commitment to shareholder returns, a practice common among mature, cash-generative companies across various industries, including large-cap pharmaceutical firms.

Corporate Governance

Legal Proceedings

• Commenced dispute resolution procedures with Vertex in Q2 2025 regarding the full amount of royalty receipts on Alyftrek net sales, as the company believes it is contractually entitled to more than received. Any amounts will be recognized only upon favorable resolution.

Related Party Transactions

• The internalization involved the acquisition of RP Manager from the Sellers, including Pablo Legorreta (CEO and Chairman), RPM I, LLC, and RP MIP Holdings, LLC (whose equity holders include named executive officers). Consideration included cash and 24.5 million RP Holdings Class E Interests, subject to vesting.
• Prior to internalization, the company paid quarterly Operating and Personnel Payments to RPM or its affiliates, equal to 6.5% of cash receipts from Royalty Investments and 0.25% of security investments. These payments ceased post-internalization.
• Pablo Legorreta, Legorreta Investments, LLC, and Legorreta Investments II LLC are guarantors under the $380 million Term Loan assumed as part of the internalization.
• Errol De Souza, Ph.D., an independent director, was a shareholder of Psyadon Pharmaceuticals, Inc., from which the company acquired a royalty interest in ecopipam in January 2024, resulting in an upfront payment of $2.5 million and potential future milestone payments to Dr. De Souza.
• Henry Fernandez, former lead independent director and chairman/CEO of MSCI, was involved in an agreement between the company and MSCI (entered April 16, 2021) to develop thematic life sciences indexes, with the company receiving a percentage of MSCI's revenues from those indexes. Financial impact to date has not been material.
• The company acquired the Legacy SLP Interest from the Continuing Investors Partnerships in exchange for issuing shares in its subsidiary, making it a special limited partner in the Legacy Investors Partnerships, which own a non-controlling interest in Old RPI.
• RPIFT owns 27,210 limited partnership interests in the Continuing Investors Partnerships, recorded as treasury interests.

Stakeholder Impact

• **Shareholders:** Experience a decline in GAAP net income and EPS, but benefit from strong Portfolio Receipts growth, significant new investments, and an active share repurchase program. The internalization aims for better alignment and governance, but also introduces new direct operating costs.
• **Employees:** Former RPM employees became Royalty Pharma employees post-internalization, benefiting from direct compensation and participation in new equity incentive plans (RP Holdings Class E Interests, Employee EPAs, Employee RSUs).
• **Customers/Partners (Biopharmaceutical Companies):** Benefit from Royalty Pharma's continued role as a leading funder of innovation, providing capital for late-stage clinical trials and new product launches, as evidenced by numerous new funding arrangements and royalty acquisitions.
• **Creditors:** The issuance of $2.0 billion in new senior unsecured notes and the assumption of a $380 million term loan increase the company's debt obligations, but the company remains in compliance with financial covenants, supported by strong cash flows.
• **Regulatory Authorities:** The company is subject to ongoing scrutiny regarding its accounting practices (effective interest method volatility) and compliance with various laws (e.g., anti-corruption, healthcare, tax), as well as the Vertex royalty dispute.

Next Steps

• Continue to evaluate and acquire new royalty opportunities to sustain business growth.
• Monitor the dispute with Vertex regarding Alyftrek royalty receipts and seek a favorable resolution.
• Recognize share-based compensation expense for RP Holdings Class E Interests over vesting periods ranging from five to nine years.
• Recognize share-based compensation expense for Employee EPAs over remaining vesting periods, generally four years.
• Fund the $100 million draw requested by Cytokinetics under tranche five of the Commercial Launch Funding in October 2025.
• Monitor the progress of development-stage product candidates, including litifilimab (Phase 3 data readout H2 2026), obexelimab (24-week data Q1 2026), trontinemab (Phase 3 initiation), daraxonrasib (Phase 3 trial initiation Q4 2025), and deucrictibant (Phase 3 topline data Q4 2025, NDA H1 2026).
• Seek renewal of shareholder authorization for allotting additional shares and disapplying preemptive rights at each year's annual general meeting.
• Continue to monitor and comply with financial covenants under debt agreements.
• Assess internal control over financial reporting for the year ending December 31, 2025, excluding cash employee compensation for RP Manager personnel.

Key Dates

Recommendation

Royalty Pharma's Q3 and YTD 2025 results present a mixed picture. While GAAP net income and EPS declined significantly, this is largely attributable to non-cash accounting adjustments related to the internalization of management and the inherent volatility of the effective interest method for financial royalty assets. Critically, the company's core cash flow metric, Portfolio Receipts, demonstrated robust growth, increasing by 15.6% for the first nine months of 2025. This strong cash generation supports continued strategic investments, with $1.7 billion deployed in new royalties and funding arrangements, and a substantial $1.2 billion in share repurchases under a new $3.0 billion program. The internalization, while impacting short-term G&A expenses, is a long-term strategic move aimed at better alignment and efficiency. The increase in R&D funding expense reflects a healthy pipeline of future royalty streams. However, the ongoing dispute with Vertex over Alyftrek royalties and competitive pressures on certain products (Tysabri, Imbruvica, Promacta) introduce elements of uncertainty. Given the strong underlying cash flow and strategic growth initiatives, but acknowledging the GAAP earnings volatility and specific product challenges, a 'hold' recommendation is appropriate. Investors should focus on the company's cash flow generation and long-term portfolio growth rather than short-term GAAP earnings fluctuations.

Keywords

Biopharmaceutical Royalties, Royalty Acquisition, Drug Development Funding, SEC 10-Q, Financial Reporting, Biotech Investments, Pharmaceutical Industry, Portfolio Receipts, Internalization, Share Repurchase, Debt Issuance, Cystic Fibrosis, Oncology, Rare Disease, Neurology, Immunology, Clinical Trials, Regulatory Approval, GAAP Accounting, Risk Factors